Loading
A phase 3 trial of Atezolizumab, Trastuzumab emtansine and Trastuzumab in HER2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy is a phase 3 interventional study registered as NCT04873362 by Hoffmann-La Roche, with 1188 participants enrolled, started 2021-05-04 and due to reach its primary completion in 2027-03-31. Interventions recorded: Atezolizumab, Trastuzumab Emtansine, Placebo and Trastuzumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Trastuzumab emtansine, Atezolizumab, Trastuzumab and the tag pipeline.
Shares Early HER2-positive breast cancer, Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Flatiron Health (Roche), Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/